MedTrace Logo

Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma

NCT03600831 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 434

Last updated 2024-01-09

No results posted yet for this study

Summary

The aim of this study is to investigate the effect of postoperative concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma.

Conditions

Interventions

DRUG

Docetaxel plus cisplatin

cisplatin 25mg/m2 on day 1 and docetaxel 25mg/m2 on day 1 weekly for 5 weeks

RADIATION

radiotherapy

radiotherapy: 50Gy (2.0 Gy/fraction, 5 days a week)

Sponsors & Collaborators

  • The Second People's Hospital of Huai'an

    collaborator OTHER

  • lian shui county People's Hospital

    collaborator UNKNOWN

  • xuyi People's Hospital

    collaborator UNKNOWN

  • Chinese People's Liberation Army No. 82 Hospital

    collaborator UNKNOWN

  • Huai'an First People's Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-20
Primary Completion
2022-05-30
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03600831 on ClinicalTrials.gov